Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrauterine misoprostol 400 mcg vs 600 mcg with oxytocin for prevention of postpartum hemorrhage at caesarean section
PACTR202505587081266Phase 1Recruiting
- Sponsor
- Self
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Self. Primary endpoint: Estimated blood loss during and after caesarean section. Started Dec 2024; status: recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202505587081266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505587081266.